Updates in the treatment of multiple myeloma

Research output: Contribution to journalArticlepeer-review


The treatment of multiple myeloma is marked by many recent advances, but for newly diagnosed patients the standard of care for induction remains the combination of a proteasome inhibitor, immunomodulatory drug, and dexamethasone. The role of a 4-drug induction regimen is still being defined, but can be considered for patients with high-risk disease. For patients who are eligible to undergo stem cell transplant, this approach remains the preferred option, but transplant can be delayed until relapse if patients prefer. In those who are not eligible for transplant, based on impressive data with daratumumab/lenalidomide/dexamethasone, this triplet should be considered as initial therapy. In patients with relapsed disease, it is important to switch treatment to new drug classes; for this, multiple combinations can be recommended. Updated guidelines now include new drugs for refractory disease: selinexor and belantamab mafodotin, both listed as "other regimens"in the NCCN Guidelines, can be considered.

Original languageEnglish (US)
Pages (from-to)648-651
Number of pages4
JournalJNCCN Journal of the National Comprehensive Cancer Network
StatePublished - May 2021

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Updates in the treatment of multiple myeloma'. Together they form a unique fingerprint.

Cite this